

Empyema Thoracis from *Salmonella* Choleraesuis

To the Editor: The clinical presentations of nontyphoidal *Salmonella* infection are protean, including gastroenteritis (most common), bacteremia, septic arthritis, osteomyelitis, and endovascular infection. (1). Despite the growing number of patients with invasive infection due to nontyphoid *Salmonella*, reports of thoracic empyema due to these organisms remain rare (2–6).

We searched the computer database of our microbiology laboratory for patients with positive pleural effusion culture from June 1997 to February 2004. Patients were included if they met the following criteria: 1) thoracentesis recovered purulent pleural fluid; 2) microorganisms identified by microscopic examination; and 3) a *Salmonella* species isolated from a pleural effusion specimen.

Isolates of *Salmonella* were identified to the serotype level, according to the Kauffman and White scheme, using somatic and flagellar antigens (Denka Seiken Co., Ltd., Tokyo, Japan) and also by conventional methods and the Phoenix System (panel type, NMIC/ID4) (Becton Dickson, Sparks, MD, USA) (7). Susceptibilities of *Salmonella* isolates to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, and trimethoprim-sulfamethoxazole were determined by the disk diffusion method. Organisms were categorized as susceptible or resistant to the antimicrobial agents tested on the basis of National Committee for Clinical Laboratory Standards (NCCLS) guidelines (8). Antimicrobial therapy was considered to be appropriate when the antimicrobial agent was active in vitro by the disk diffusion susceptibility method against a *Salmonella* isolate.

During the study, 973 patients with a diagnosis of empyema thoracis were identified; 12 (1.23%) of these patients, including 9 men and 3 women, were infected with *Salmonella* species. The clinical characteristics of the 12 patients are summarized in the online Appendix Table (available from http://www.cdc.gov/ncidod/eid/vol11no09/05-0030_app.htm). The median age was 49 years; 1 patient was >65 years of age. Underlying diseases were present in all patients, including 7 with malignancy, 5 with gallstones, and 3 each with diabetes mellitus and chronic renal failure. Five patients had used antacids and 3 patients had received chemotherapy or steroids. Ten patients (83.3%) were immunocompromised and had a variety of illnesses, including malignancy, liver cirrhosis, and diabetes mellitus. Common symptoms were dyspnea (83.3%), fever (75%), and cough (50%). Analysis of pleural effusion showed a median leukocyte count of 25,600/ μ L, a lactate dehydrogenase level of 513 U/L, and a glucose level of 88 mg/dL. Gram staining was conducted on 3 patients' pleural effusion but none of them showed positive results.

Twenty-three *Salmonella* isolates were recovered as the sole pathogen from various clinical specimens, including pleural effusion (15 isolates), blood (6 isolates), ascites (1 isolate), and aortic wall (1 isolate). Among the 12 patients with empyema thoracis, 4 had *Salmonella enterica* serotype Typhimurium (*S. Typhimurium*) and 1 had group C2 *Salmonella* during 1997–1999; 7 patients had *Salmonella enterica* serotype Choleraesuis (*S. Choleraesuis*) after 1998. All *S. Typhimurium* and group C2 *Salmonella* were isolated from pleural effusion specimens, but *S. Choleraesuis* was isolated from multiple extrapulmonary sites including blood, ascites, and aortic wall (Online Table). Although the number of study cases is limited, it may suggest that *S.*

Choleraesuis is more invasive than 2 other *Salmonella* species.

Among the *S. Choleraesuis* isolates recovered from 7 patients, 2 were resistant to ampicillin and sulfamethoxazole-trimethoprim, 3 were resistant to chloramphenicol, 1 was resistant to ciprofloxacin, and all were susceptible to cefotaxime. All *S. Typhimurium* isolates were susceptible to sulfamethoxazole-trimethoprim, ciprofloxacin, and cefotaxime. Two of the 4 patients had isolates that were resistant to chloramphenicol, and 2 other patients had isolates that were resistant to ampicillin. The group C2 *salmonella* isolate was resistant to chloramphenicol only.

Among the 12 *Salmonella* isolates from patients with empyema thoracis, 9 were resistant to >1 commonly used antimicrobial. Treatment and outcome information was available for 11 of the 12 patients. All 11 patients received antimicrobials drugs (median duration 35 days); this therapy was appropriate in 9 of 11 patients. Six patients had thoracentesis, 2 had close tube thoracostomy, and 1 had open drainage. One of the 4 patients with *S. Typhimurium* empyema who did not receive appropriate antimicrobial drugs died. In contrast, 4 (57%) of the 7 patients with *S. Choleraesuis* infection, including 1 who did not receive appropriate antimicrobial therapy, died. Another factor related to outcome was drainage. One (20%) of the 5 patients who underwent tube thoracostomy or thoracoscopy died, while 3 (50%) of the 6 patients who underwent thoracentesis died. All 3 of these patients had *S. Choleraesuis*.

Most (92%) of our patients were <65 years of age. These data indicate that *Salmonella* should be considered as a potential cause of thoracic empyema, even in younger patients, especially in the presence of malignancy or hepatobiliary disease. More than half of our patients had used antacids or had suffered from gallstones. This finding suggests that susceptibility to

Salmonella infection may be increased by alterations in the gastrointestinal tract, including decreased gastric acidity and chronic gastrointestinal disease. Leukocytosis was noted in 25% of patients. In fact, two thirds of the patients had a normal leukocyte count with immature leukocytes, which may be attributable to their relatively impaired cell-mediated immunity.

The predominant organism in this series was *S. Choleraesuis*, followed by *S. Typhimurium*. In Taiwan, the rate of resistance of *S. Choleraesuis* to ampicillin, chloramphenicol, or sulfamethoxazole-trimethoprim increased to approximately 90% for all 3 drugs and the rate of resistance to ciprofloxacin was from 7.7% to 59% (5–7). The resistance rate of *S. Choleraesuis* to ciprofloxacin in this study was similar to our previous report (7).

Nine of the 11 patients who completed follow-up information received appropriate antimicrobial drugs with drainage; however, 4 died. These 4 deaths (57%) were due to *S. Choleraesuis*-related empyema; 3 patients had underlying malignancy. Although appropriate antimicrobial drugs were used, our data suggest that more aggressive treatment with open drainage of the pleural effusion might have contributed to a better outcome than closed tube thoracostomy or simple thoracocentesis alone. In contrast to *S. Choleraesuis*-related infection, all 4 patients with non-*S. Choleraesuis*-related thoracic empyema survived. One of these patients did not receive appropriate antimicrobial drug treatment, but did have adequate drainage with simple thoracocentesis. This suggests adequate and aggressive drainage of pleural effusion may be as important as appropriate antimicrobial drugs. However, the overall death rate (36%) in this study was still higher than that of other reports (9). This might have been due to the high number of immunocompromised patients in this study.

In conclusion, thoracic empyema is a rare complication of nontyphoid *Salmonella* infection and is closely associated with an immunocompromised condition, even in patients <65 years of age. Higher rates of resistance and death were noted in patients with empyema thoracic caused by *S. Choleraesuis*. Early diagnosis, appropriate antimicrobial drug therapy, and aggressive drainage are necessary to improve the outcome of patients with thoracic empyema due to *S. Choleraesuis*.

Chih-Cheng Lai,* Li-Na Lee,*
Po-Ren Hsueh,* Chong-Jen Yu,*
and Pan-Chyr Yang*

*National Taiwan University Hospital,
Taipei, Taiwan, Republic of China

References

- Hohmann EL. Nontyphoid salmonellosis. *Clin Infect Dis*. 2001;32:263–9.
- Chen KY, Hsueh PR, Liaw YS, Yang PC, Luh KT. A 10-year experience with bacteriology of acute thoracic empyema: emphasis on *Klebsiella pneumoniae* in patients with diabetes mellitus. *Chest*. 2000;117:1685–9.
- Samonis G, Maraki S, Kouroussis C, Mavroudis D, Georgoulas V. *Salmonella enterica* pneumonia in a patient with lung cancer. *J Clin Microbiol*. 2003;41:5820–2.
- Biendo M, Laurans G, Thomas D, Dechepy O, Hamdad-Daoudi F, Canarelli B, et al. Regional dissemination of *Salmonella enterica* serovar Enteritidis is season dependent. *Clin Microbiol Infect*. 2003;9:360–9.
- Chiu CH, Wu TL, Su LH, Chu C, Chia JH, Kuo AJ, et al. The emergence in Taiwan of fluoroquinolone resistance in *Salmonella enterica* serotype Choleraesuis. *N Engl J Med*. 2002;346:413–9.
- Chiu CH, Su LH, Chu C. *Salmonella enterica* serotype Choleraesuis: epidemiology, pathogenesis, clinical disease, and treatment. *Clin Microbiol Rev*. 2004;17:311–22.
- Hsueh PR, Teng LJ, Tseng SP, Chang CF, Wan JH, Yan JJ, et al. Ciprofloxacin-resistant *Salmonella enterica* Typhimurium and *Choleraesuis* from pigs to humans, Taiwan. *Emerg Infect Dis*. 2004;10:60–8.
- National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial disk susceptibility test; approved standards—eighth edition. M2-A8. Wayne (PA): The Committee.
- Cohen JI, Bartlett JA, Corey GR. Extra-intestinal manifestations of *Salmonella* infection. *Medicine (Baltimore)*. 1987;66:349–88.

Address for correspondence: Po-Ren Hsueh, Departments of Laboratory Medicine and Internal Medicine, National Taiwan University, No 7, Chung-Shan South Road, 100 Taipei, Taiwan, Republic of China; fax: 886-2-23224263; e-mail: hsporen@ha.mc.ntu.edu.tw

Asymptomatic *Yersinia pestis* Infection, China

To the Editor: Plague is one of the oldest identifiable diseases. Modern public health measures and effective antimicrobial treatments have led to a decrease in plague cases worldwide. However, plague remains endemic in many natural foci. Since the early 1990s, the World Health Organization (WHO) has reported a steadily increasing trend in human plague cases, which has resulted in the recognition of plague as a reemerging disease (1). The emergence of antimicrobial drug-resistant strains of *Yersinia pestis*, along with an increasing number of plague cases, remind us that plague still poses a serious public health threat (2,3). In China, human cases of plague have been reported to WHO nearly every year from 1989 to 2003; these account for 9.5% of cases and 15.5% of deaths from this disease in Asia (1). Human cases of plague in China are usually caused by contact with plague-infected rodents. Here, we report the results of a serologic survey by using 3 methods (passive hemagglutination assay, Western blot, and protein microarray analysis) in marmot hunters in Qinghai Province, China.

One hundred twenty serum samples were collected in 2 villages in